Fundamentals in Urology (2017)

June 17, 2017 to June 20, 2017

The Fundamentals in Urology course is designed to apply basic science knowledge and principles in development of treatment algorithms. This 4-day course will provide attendees with valuable skills in developing a rational methodological approach to application of knowledge which will contribute to positive outcomes for patients. Attendees will discover the importance of the study of basic sciences and how it transfers into the lifelong learning process and medical practice. This course is designed to ensure a fundamental knowledge of the "why" behind a broad expanse of general urologic conditions. A thorough knowledge of the basic science behind the treatments will allow for better counseling and education of patients by all clinical urologic practitioners.

Target Audience

  • Urology residents
  • Allied Health Professionals

Learning Objectives

After attending this course, participants will be able to:

 

Nephrolithiasis and Infections

  1. Recognize the basic pathophysiology of nephrolithiasis.
  2. Identify the indications and options for the medical evaluation of recurrent and first time stone formers.
  3. Establish an effective algorithm for the medical management of nephrolithiasis.
  4. Distinguish the appropriate timing of diagnostic methods for treatment of bacteria and fungi in the urinary tract.

 

Incontinence, Ethics, Obstruction, and Pelvic Pain

  1. Recall the pathophysiology of pelvic organ prolapse and stress incontinence.
  2. Describe how to treat pelvic organ prolapse and stress incontinence conditions.
  3. Review foundational concepts of bioethics.
  4. Define the meaning of “profession”.
  5. Discuss key aspects of consent, capacity, research and ethics.
  6. Identify how to apply consent, capacity, research and ethics to the practice of urology.
  7. Recognize the role of prophylacitic antibiotics and lower urinary tract imaging for prenatal urinary tract dilation.
  8. Define the true incidence of IC/BPS and CP/CPPS in the US population.
  9. Recall what is currently believed about the pathophysiology of chronic pelvic pain.
  10. Recognize how to use the AUA guidelines to develop a treatment plan for patients with IC/BPS and CP/CPPS.
  11. Describe current research in pelvic pain and possible new treatment options.

 

Minimally Invasive Surgery, BPH, Outcomes and Pediatrics

  1. Identify the physics underlying laser energy, complications occurring due to pneumoperitoneum, and optimizing delivery of shock wave energy.
  2. Define the medical therapies designed to address benign enlargement of the prostate.
  3. Explain the basic development of the lower and upper urinary tract including the bladder, kidney and ureters.
  4. Identify clinical situations that may be encountered if aberrant development occurs in any of the above organ systems.
  5. Recognize the validity of randomized clinical trials.
  6. Recognize how to apply the results of outcomes research to clinical practice.

 

Imaging and Prostate Cancer

  1. Describe the history of M1 Prostate cancer therapies.
  2. Identify basics in ADT management.
  3. Discuss basic science and clinical outcomes of new therapies.
  4. Identify the appropriate indications for MRI and the basic MRI sequences used in urinary tract imaging.
  5. Distinguish benign from malignant renal masses.
  6. Recognize how an MRI of the prostate and urethra can be useful and the key features of prostate tumor on MRI.

 

Adrenal and Renal Physiology, Bowel Diversions, and Bladder Cancer

  1. Describe how fundamentals of adrenal anatomy and physiology integrate into the care of the urologic patient.
  2. Discuss renal physiology for the urologist, especially for the following pathologic states: TUR syndrome, upper urinary tract obstruction, post-obstructive diuresis, pregnancy, renovascular hypertension, and juxtaglomerular tumor.
  3. Review the major genetic alterations that are present in bladder cancers.
  4. Define “intrinsic subtypes”.
  5. Discuss their implications for disease heterogeneity and precision medicine
  6. Review current understanding of immunotherapy for treatment of bladder cancer.
  7. Explain rationale for choosing a urinary diversion based on the metabolic derangements associated with each segment of bowel.

 

Male Infertility, Disorders of Differentiation, and Kidney Cancer

  1. Explain male reproductive anatomy and physiology.
  2. Discuss a basic clinical overview of male reproductive medicine and surgery.
  3. Describe the current clinical and surgical management of all types of localized as well as advanced kidney cancer.

 

PSA and the Prostate, Neurogenic Bladder, and Reproductive Biology

  1. Review the current data on the controversies, clinical trials and laboratory testing for prostate cancer screening in asymptomatic men.
  2. Explain lower urinate tract neurobiology and how disease processes, such as neurologic disease; result in predictable lower urinary tract dysfunction.
  3. Describe penile anatomy and the physiology of erection.
  4. Describe the major causes of erectile dysfunction.
  5. Identify the basic classification, diagnosis and treatment of female sexual dysfunction.

 

Course summary
Available credit: 
  • 25.75 AMA PRA Category 1 Credit™
  • 25.75 Non-Physician Participation
Course opens: 
03/24/2017
Course expires: 
06/17/2019
Event starts: 
06/17/2017 - 8:00am EDT
Event ends: 
06/20/2017 - 11:45am EDT
List Price:
$805.00
Add to calendar: 
Rating: 
0

Saturday, June 17, 2017

 

7:00 – 8:00 am                  Continental Breakfast and Registration

 

8:00 – 8:30 am                  Welcome, Introduction

                                              Tracey L. Krupski, MD, MPH; Jay D. Raman, MD, FACS

 

Session: Nephrolithiasis and Infections

 

8:30 – 9:30 am                  Nephrolithiasis 1: The Physiology, Metabolic Work-up and Treatment of Stones

                                             Glenn M.  Preminger, MD

 

           9:30 – 9:45 am                  Break

 

9:45 - 10:30 am                 Nephrolithiasis 2: The Physiology, Metabolic Work-up and Treatment of Stones

                                              Glenn M. Preminger, MD

 

10:30 – 11:35 am             UTIs: Pattern and Pathophysiology

                                             Michel A. Pontari, MD

 

11:35 – 11:50 am             AUA Update

                                            Victor Nitti, MD

 

11:50 am – 12:50 pm       Lunch & Learn with the Experts (Others on Own)

Session: Incontinence, Ethics, Obstruction, and Pelvic Pain

12:50 – 1:55 pm                Pelvic Organ Prolapse and SUI: Mechanisms and Mechanics

                                             Victor Nitti, MD

 

1:55 – 2:50 pm                  Uro-Ethics

                                              Eric A. Singer, MD

 

           2:50 – 3:00 pm                  Break

 

3:00 – 4:05 pm                  Obstructive Uropathy: Valves and UPJO

                                             C.D. Anthony Herndon, MD, FAAP, FACS

 

4:05 – 5:15 pm                  Interstitial Cystitis and Disorders of Pelvic Pain

                                              Robert J. Evans, MD, FACS

 

6:00 – 7:00 pm                  Reception

                                              Omni Hotel Atrium

 

 

Sunday, June 18, 2017

 

7:00 – 8:00 am                  Continental Breakfast

 

Session: Minimally Invasive Surgery, BPH, Outcomes and Pediatrics

 

8:00 – 9:05 am                  Lasers, Laparoscopes, and Lithotripters: The Science of Minimally Invasive Urology

                                              Jay D. Raman, MD, FACS

 

9:05 – 10:10 am                Medical Treatment for BPH

                                              Richard K. Lee, MD

 

           10:10 – 10:25 am             Break

 

10:25 - 11:30 am              Embryology and Congenital Anomalies

                                             Patricio C. Gargollo, MD

 

11:30 am – 12:20 pm      Application of Outcomes Research to Urologic Patients

                                            Charles D. Scales Jr., MD

 

12:20 – 1:20 pm                Lunch & Learn with the Experts (Others on Own)

Session: Imaging and Prostate Cancer

1:20 – 1:40 pm                  AUA Update: Office of Research

                                             Carolyn J.M. Best, PhD

 

1:40 – 2:30 pm                  MRI for Urologists I

                                             Afshan Ornan, MD

 

           2:30 – 2:45 pm                  Break

 

2:45 – 3:30 pm                  MRI for Urologists II

                                              Afshan Ornan, MD

 

3:30 – 4:45 pm                  Management of Advanced Prostate Cancer: Drugs, Mechanisms, Disease, Epidemiology and                                                   Molecular Mechanisms

                                              Michael B. Williams, MD

 

Monday, June 19, 2017

 

7:00 – 8:00 am                  Continental Breakfast

 

Session: Adrenal and Renal Physiology, Bowel Diversions, and Bladder Cancer

 

8:00 – 9:05 am                  Adrenal Physiology 

                                              Alexander Kutikov, MD, FACS

 

9:05 – 10:10 am                Renal Physiology Changes in Pathologic States

                                             Necole Marie Streeper, MD

 

            10:10 – 10:25 am             Break

 

10:25 – 11:30 am             Basic Science of Bladder Cancer

                                             Trinity J. Bivalacqua, MD, PhD

 

11:30 am – 12:35 pm      Bowel Diversions: Physiology Underlying Electrolyte Abnormalities

                                             Tracey L. Krupski, MD, MPH

 

Session: Male Infertility, Disorders of Differentiation, and Kidney Cancer

 

          12:35 – 1:35 pm                Lunch & Learn with the Experts (Others on Own)

 

1:35 – 2:40 pm                  Male Infertility

                                             Puneet Masson, MD

 

2:40 – 3:45 pm                  Disorders of Sexual Differentiation

                                             Duong D. Tu, MD

 

          3:45 – 4:00 pm                  BREAK

 

4:00 - 5:30 pm                   Molecular Genetics and Principles of Molecular Therapeutics of Kidney Cancer

                                             W. Marston Linehan, MD

 

Tuesday, June 20, 2017

 

7:00 – 8:00 am                  Continental Breakfast

 

Session: PSA and the Prostate, Neurogenic Bladder, and Reproductive Biology

 

8:00 – 9:05 am                  PSA, Urine Markers and the Science of Cancer Screening

                                             Leonard G. Gomella, MD

 

9:05 – 10:40 am                Lower Urinary Tract Neurobiology and Functional Bladder Disorders

                                              William Stuart Reynolds, MD, MPH

 

10:40 – 11:45 am             Reproductive Biology and Sexual Dysfunction in Men and Women

                                             Ryan Smith, MD

 

         11:45 am                             Adjourn

Omni Charlottesville Hotel
Charlottesville, VA
United States

Name

Company

Role

Financial

Trinity J. Bivalacqua, MD

heat biologic

 

Scientific Study or Trial

 

No

 

photocure

Meeting Participant or Lecturer, Scientific Study or Trial

No

Taris

Scientific Study or Trial

No

Robert J. Evans, MD

 

allergan

Scientific Study or Trial

Yes

urigen

Investment Interest

Yes

TARIS

Scientific Study or Trial

Yes

aquinox

 

Consultant or Advisor, Scientific Study or Trial

 

Yes

Patricio C. Gargollo, MD

 

Nothing to disclose.

Leonard G. Gomella, MD

 

Astellas

Consultant or Advisor

Yes

Janssen

Consultant or Advisor

Yes

Wolters Kluwer

Health Publishing

Yes

McGraw Hill

Health Publishing

Yes

Merck Manual

Health Publishing

Yes

Canadian Journal of Urology

Health Publishing

Yes

MDx Health

Consultant or Advisor

Yes

Merck Pharmaceuticals

Consultant or Advisor

Yes

Bayer

Consultant or Advisor

Yes

Mikel L. Gray, Ph.D.

Laborie Medical

Meeting Participant or Lecturer

Yes

3M Inc.

Consultant or Advisor

Yes

C.D. Anthony Herndon, MD, FAAP, FACS

 

Nothing to disclose.

Tracey Krupski, MD

Argos

Scientific Study or Trial

No

NCI- RAZOR

Scientific Study or Trial

No

Eleven Biotherapeutics

Scientific Study or Trial

Yes

American Cancer Society

Scientific Study or Trial

Yes

Alexander Kutikov, MD

UrologyMatch.com LLC

Leadership Position

Yes

Visible Health, Inc

Leadership Position

Yes

Genomic Health, Inc

Consultant or Advisor, Meeting Participant or Lecturer

Yes

Novartis, Inc

Consultant or Advisor

Yes

Richard K. Lee, MD

Nothing to disclose

W. Marston Linehan, MD

Nothing to disclose.

Puneet Masson, MD

Nothing to disclose.

Victor Nitti, MD

Astellas

Health Publishing, Scientific Study or Trial

No

Allergan

Health Publishing, Scientific Study or Trial

No

Serenity Pharmaceuticals

Investment Interest

Yes

Cook Myosite

Scientific Study or Trial

No

Medtronic

Scientific Study or Trial

No

Afshan Ornan ,M.D.

Nothing to disclose.

 

 

Gladell Paner, MD

Amirsys, Inc.

Health Publishing

Yes

Glenn M. Preminger, MD

Boston Scientific

Consultant or Advisor

Yes

Endourological Society

Leadership Position

Yes

UpToDate

Health Publishing

Yes

Retrophin

Consultant or Advisor, Meeting Participant or Lecturer

Yes

Michel Pontari, MD

Lilly

Consultant or Advisor

Yes

Aquinox

Consultant or Advisor, Scientific Study or Trial

Yes

Jay D. Raman, MD

American Kidney Stone Management

Investment Interest

Yes

Pacific Edge Biotechnology

Consultant or Advisor, Scientific Study or Trial

No

William Stuart Reynolds, MD, MPH

AMAG Pharmaceuticals

Meeting Participant or Lecturer

Yes

Valeant Pharmaceuticals

Consultant or Advisor, Meeting Participant or Lecturer

Yes

Pfizer Pharmaceuticals

Meeting Participant or Lecturer, Other

Yes

Charles D. Scales Jr., MD

NIH/National Institute on Aging

Scientific Study or Trial

Yes

Society of Urology Chairpersons and Program Directors

Scientific Study or Trial

Yes

Filament Biosolutions

Scientific Study or Trial

No

NIH/ National Institute of Diabetics and Digestive and Kidney Diseases

Scientific Study or Trial

No

Gilead

Consultant or Advisor

Yes

Astra-Zeneca

Scientific Study or Trial

Yes

Eric A. Singer, MD

Nothing to disclose.

Ryan Smith, MD

Nothing to disclose.

Necole M Streeper, M.D.

Nothing to disclose.

Duong D. Tu, M.D.

Nothing to disclose.

Michael B. Williams, M.D.

Astellas

Scientific Study or Trial

No

Jannsen

Scientific Study or Trial

No

Pacific Edge Diagnostics

Consultant or Advisor

Yes

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

  • Full Course: The American Urological Association designates this live activity for a maximum of 25.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • Pathology AND Urodynamics: The American Urological Association designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 25.75 AMA PRA Category 1 Credit™
  • 25.75 Non-Physician Participation

Price

List Price:
$805.00
Please login or register to take this course.